Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, May 11 2023

Full Issue

Buprenorphine, Effective For Opioid Addiction, Is Underprescribed: Study

From 2016 through 2019, little more than 20% of patients diagnosed with opioid use disorder filed prescriptions for buprenorphine, a large new study found. Media outlets note the study says underprescribing is worse for Black patients.

The New York Times: Addiction Treatment Medicine Is Vastly Underprescribed, Especially By Race, Study Finds 

Despite the continuing rise in opioid overdose deaths, one of the most effective treatments for opioid addiction is still drastically underprescribed in the United States, especially for Black patients, according to a large new study. From 2016 through 2019, scarcely more than 20 percent of patients diagnosed with opioid use disorder filled prescriptions for buprenorphine, the medication considered the gold standard in opioid addiction treatment, despite repeated visits to health care providers, according to the study, which was published Wednesday in the New England Journal of Medicine. (Hoffman, 5/10)

Stat: Black Patients With Opioid Addiction Lack Equal Access To Treatment

Black people are far less likely than other Americans to receive buprenorphine, a key medication for treating opioid use disorder, according to a new study. White patients in need of addiction care were prescribed buprenorphine at more than twice the rate of Black patients in the six months preceding an addiction-related health emergency, according to the analysis. The treatment gap continued at a similar rate in the six months after an overdose, hospitalization, or admission to a rehab facility. (Facher, 5/10)

More on the opioid and 'tranq' crisis —

NPR: Trump's 2024 Campaign Promise To Execute Drug Offenders Is A Long Shot

Former President Donald Trump spoke to New Hampshire voters during a CNN town hall held at St. Anselm College in Manchester Wednesday night. Audience members asked how he would tackle issues like abortion, Second Amendment rights, immigration and more. But nobody brought up the opioid crisis plaguing the Granite State. (Jones and Speak, 5/10)

Los Angeles Times: Sheriff's Dept. To Track Presence Of Flesh-Eating Street Drug Appearing In Los Angeles

Amid troubling signs that a dangerous sedative known as “tranq” has spread even further into the local street drug supply, the Los Angeles County Sheriff’s Department has launched a pilot program to better document the drug’s presence. Xylazine is an animal tranquilizer that began appearing several years ago in illicit pills and powders on the East Coast. It’s been linked to deaths across the country and can cause human tissue to rot, leaving users with grisly wounds that sometimes lead to amputations. (Blakinger, 5/10)

WUSF Public Media: A New Program Will Provide Florida First Responders With Free Naloxone

An initiative launched by Attorney General Ashley Moody will provide Florida's first responders with free naloxone, a medication that can reverse the effects of an opioid overdose. The “Helping Heroes” program will provide naloxone to law enforcement, firefighters and paramedics at select Walmart pharmacies in Florida, according to a press release from the attorney general‘s office. Moody announced the initiative Tuesday – on National Fentanyl Awareness Day – in Clearwater. (Pinos, 5/10)

In news about psychedelic drugs —

Columbus Dispatch: Ohio State To Grow Psychedelic Mushrooms Under First-Ever DEA License

Ohio State University is about to grow psychedelic mushrooms. For scientific research, people. Ohio State, alongside the mental health and wellness research and development company Inner State Inc., was awarded the first-ever license by the U.S. Drug Enforcement Agency to grow whole psilocybin mushrooms. The mushrooms will be used in the study of mental health treatment capabilities with naturally grown psychedelic mushrooms. (Hendrix, 5/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF